Office of Blood Research and Review, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.
Office of Blood Research and Review, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.
J Mol Diagn. 2024 Jun;26(6):456-466. doi: 10.1016/j.jmoldx.2024.02.005. Epub 2024 Mar 16.
Patients who carry Rhesus (RH) blood group variants may develop Rh alloantibodies requiring matched red blood cell transfusions. Serologic reagents for Rh variants often fail to specifically identify variant Rh antigens and are in limited supply. Therefore, red blood cell genotyping assays are essential for managing transfusions in patients with clinically relevant Rh variants. Well-characterized DNA reference reagents are needed to ensure quality and accuracy of the molecular tests. Eight lyophilized DNA reference reagents, representing 21 polymorphisms in RHD and RHCE, were produced from an existing repository of immortalized B-lymphoblastoid cell lines at the Center for Biologics Evaluation and Research/US Food and Drug Administration. The material was validated through an international collaborative study involving 17 laboratories that evaluated each DNA candidate using molecular assays to characterize RHD and RHCE alleles, including commercial platforms and laboratory-developed testing, such as Sanger sequencing, next-generation sequencing, and third-generation sequencing. The genotyping results showed 99.4% agreement with the expected results for the target RH polymorphisms and 87.9% for RH allele agreement. Most of the discordant RH alleles results were explained by a limited polymorphism coverage in some genotyping methods. Results of stability and accelerated degradation studies support the suitability of these reagents for use as reference standards. The collaborative study results demonstrate the qualification of these eight DNA reagents for use as reference standards for RH blood group genotyping assay development and analytical validation.
携带 Rh(RH)血型变异体的患者可能会产生需要匹配的红细胞输血的 Rh 同种抗体。Rh 变异体的血清学试剂通常无法特异性识别变异 Rh 抗原,并且供应有限。因此,红细胞基因分型检测对于管理具有临床相关 Rh 变异体的患者的输血至关重要。需要经过良好表征的 DNA 参考试剂来确保分子检测的质量和准确性。8 种冻干 DNA 参考试剂,代表 RHD 和 RHCE 中的 21 种多态性,是从美国食品和药物管理局/美国食品和药物管理局中心的永生 B 淋巴细胞系现有存储库中生产的。该材料通过涉及 17 个实验室的国际合作研究进行了验证,这些实验室使用分子检测评估每个 DNA 候选物,以表征 RHD 和 RHCE 等位基因,包括商业平台和实验室开发的测试,如 Sanger 测序、下一代测序和第三代测序。基因分型结果显示,目标 RH 多态性的符合率为 99.4%,RH 等位基因的符合率为 87.9%。大多数不一致的 RH 等位基因结果可通过某些基因分型方法中有限的多态性覆盖来解释。稳定性和加速降解研究的结果支持这些试剂适合用作参考标准。合作研究结果表明,这 8 种 DNA 试剂可用于 RH 血型基因分型检测开发和分析验证的参考标准。